Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blind, Double-dummy, Randomized, Single-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine

NCT04384367 is registered in ClinicalTrials.gov with Eurofarma Laboratorios S.A. as lead sponsor.

NCT NCT04384367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04384367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blind, Double-dummy, Randomized, Single-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine
Lead sponsor
Eurofarma Laboratorios S.A.
Phase
Phase 3
Overall status
Completed
Start date
December 30, 2022
Completion date
November 30, 2024
Enrollment
2,068 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

migraine